|
| |
AtheroGenics IncorporatedAtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma.
AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clinical testing arena to ultimately establish the safety and efficacy of novel compounds that address serious unmet medical needs
| Contact Details: |
| 8995 Westside Parkway |
| Alpharetta |
| |
| 30004 |
| United States of America |
| Tel: | 678 336 2500 |
| Fax: | 770 447 1886 |
| Email: | investor@atherogenics.com. |
| WWW: | www.atherogenics.com/
|
| |
Recent Publications by AtheroGenics Incorporated: |  |
Sulforaphane inhibits TNF-alpha-induced activation of p38 MAP kinase and VCAM-1 and MCP-1 expression in endothelial cells.
OBJECTIVE AND DESIGN: To investigate the effects of sulforaphane on... | 30th September, 2009
| Discovery Research, AtheroGenics, Inc., 8995 Westside Parkway, Alpharetta,
| Inflamm Res. 2009 Aug;58(8):513-21. Epub 2009 Mar 11.
DOI Direct Link |
Carboxylated, heteroaryl-substituted chalcones as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
Starting from a simple chalcone template, structure-activity relationship... | 28th April, 2007
| AtheroGenics, Inc., 8995 Westside Parkway, Alpharetta, Georgia 30004, USA.
| J Med Chem. 2007 Mar 22;50(6):1304-15. Epub 2007 Feb 27.
DOI Direct Link |
Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression.
The antioxidant response element (ARE) is a transcriptional control... | 2nd June, 2006
| Discovery Research, AtheroGenics, Incorporated, Alpharetta, GA 30004, USA.
| Am J Physiol Heart Circ Physiol. 2006 May;290(5):H1862-70. Epub 2005 Dec
DOI Direct Link |
Atherosclerosis is an inflammatory disorder after all.
Inflammation has been increasingly recognized as an important player in... | 11th May, 2006
| AtheroGenics, Inc., 8995 Westside Parkway, Alpharetta, Georgia 30004, USA.
| Curr Top Med Chem. 2006;6(2):93-102.
|
Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease.
Inflammation has been increasingly recognized as an important player in... | 17th February, 2006
| Discovery Medicinal Chemistry, AtheroGenics, Inc., 8995 Westside Parkway,
| J Med Chem. 2006 Jan 12;49(1):1-22.
DOI Direct Link |
→View more AtheroGenics Incorporated research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 386 times since April 2007, the link to the organisation's website has been followed 72 times Search for more companies in Alpharetta Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for AtheroGenics Incorporated |
